Results 61 to 70 of about 107,280 (285)
Proteasome Inhibitors in Waldenström Macroglobulinemia
Hematology/Oncology Clinics of North America, 2018 Waldenström macroglobulinemia (WM) remains an incurable B-cell lymphoproliferative disorder, yet therapy is only considered for patients with symptomatic disease. Primary therapy options for WM include combinations based on anti-CD20 monoclonal antibodies, mainly rituximab. However, proteasome inhibitors have become an important part of WM therapy both
Kastritis, Efstathios +1 more
openaire +5 more sources
Day/night variations of myeloid and lymphoid cell subsets in the murine inguinal lymph node
FEBS Open Bio, EarlyView.The circadian system is involved in the temporal regulation of the immune system. Our study reveals that two innate immune populations, NKT cells and neutrophils, predominate at the beginning of the day in healthy mice, highlighting how the time of day influences immune responses.
Paula M. Wagner +6 more
wiley +1 more source
Autophagosome marker, LC3, is released extracellularly via several distinct pathways
FEBS Open Bio, EarlyView.This study establishes a novel HiBiT‐tagging system for ultrasensitive detection of LC3, revealing multiple pathways for its extracellular secretion. It demonstrates that LC3 is released via both autophagy‐dependent and ‐independent mechanisms, including a novel route for nonlipidated LC3‐I.
Koki Saito +3 more
wiley +1 more source
DDX3X induces mesenchymal transition of endothelial cells by disrupting BMPR2 signaling
FEBS Open Bio, EarlyView.Elevated DDX3X expression led to downregulation of BMPR2, a key regulator of endothelial homeostasis and function. Our co‐immunoprecipitation assays further demonstrated a molecular interaction between DDX3X and BMPR2. Notably, DDX3X promoted lysosomal degradation of BMPR2, thereby impairing its downstream signaling and facilitating endothelial‐to ...
Yu Zhang +7 more
wiley +1 more source
SIRT4 positively regulates autophagy via ULK1, but independently of HDAC6 and OPA1
FEBS Open Bio, EarlyView.Cells expressing SIRT4 (H161Y), a catalytically inactive mutant of the sirtuin SIRT4, fail to upregulate LC3B‐II and exhibit a reduced autophagic flux under stress conditions. Interestingly, SIRT4(H161Y) promotes phosphorylation of ULK1 at S638 and S758 that are associated with inhibition of autophagy initiation.
Isabell Lehmkuhl +13 more
wiley +1 more source
Hsp90 inhibition decreases mitochondrial protein turnover.
PLoS ONE, 2007 BackgroundCells treated with hsp90 inhibitors exhibit pleiotropic changes, including an expansion of the mitochondrial compartment, accompanied by mitochondrial fragmentation and condensed mitochondrial morphology, with ultimate compromise of ...
Daciana H Margineantu +3 more
doaj +1 more source
In situ Electrochemical Evaluation of the Interaction of dsDNA with the Proteasome Inhibitor Anticancer Drug Bortezomib [PDF]
, 2023 Mihaela-Cristina Bunea +2 more
openalex +1 more source
FEBS Open Bio, EarlyView.Mouse pre‐implantation development involves a transition from totipotency to pluripotency. Integrating transcriptomics, epigenetic profiling, low‐input proteomics and functional assays, we show that eight‐cell embryos retain residual totipotency features, whereas cytoskeletal remodeling regulated by the ubiquitin‐proteasome system drives progression ...
Wanqiong Li +8 more
wiley +1 more source
Meta‐analysis fails to show any correlation between protein abundance and ubiquitination changes
FEBS Open Bio, EarlyView.We analyzed over 50 published proteomics datasets to explore the relationship between protein levels and ubiquitination changes across multiple experimental conditions and biological systems. Although ubiquitination is often associated with protein degradation, our analysis shows that changes in ubiquitination do not globally correlate with changes in ...
Nerea Osinalde +3 more
wiley +1 more source
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
BMC Cancer, 2018 Background Multiple myeloma (MM) patients with t(14;20) have a poor prognosis and their outcome has not improved following the introduction of bortezomib (Bzb).
Ya-Wei Qiang +8 more
doaj +1 more source